Cara Therapeutics Posts Positive Trial Data For Korsuva Injection To Treat Pruritus

Cara Therapeutics (CARA) on Wednesday reported positive topline data from the KALM-1 phase 3 trial of Korsuva Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP).

Shares surged 18% to $21.22 in pre-market trade.

The company is “encouraged by the early anti-pruritic response with Korsuva Injection, which resulted in statistically significant separation from placebo after only one week of treatment and a sustained significant benefit through 12 weeks,” said Cara CEO Derek Chalmers in a statement.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

CKD-aP is an intractable, systemic itch condition that occurs with high frequency and intensity in patients undergoing hemodialysis and peritoneal dialysis.

“We look forward to reporting topline data from our second global phase 3 trial, KALM-2, in the second half of this year and, assuming positive results, moving towards an NDA submission as quickly as possible thereafter,” Chalmers said.